List of Tables
    Table 1. Oncology Biosimilars CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Oncology Biosimilars Market Trends
    Table 3. Oncology Biosimilars Market Drivers
    Table 4. Oncology Biosimilars Market Challenges
    Table 5. Oncology Biosimilars Market Restraints
    Table 6. Global Oncology Biosimilars Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Oncology Biosimilars Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Oncology Biosimilars Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Oncology Biosimilars Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Oncology Biosimilars Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Oncology Biosimilars Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Oncology Biosimilars Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Oncology Biosimilars Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Oncology Biosimilars Sales Share by Manufacturer, 2017-2022
    Table 15. Global Oncology Biosimilars Price by Manufacturer (2017-2022) & (US$/Unit)
    Table 16. Global Oncology Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Oncology Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2021)
    Table 18. Top Players of Oncology Biosimilars in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Oncology Biosimilars Product Type
    Table 20. Date of International Manufacturers Enter into Oncology Biosimilars Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Oncology Biosimilars Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Oncology Biosimilars Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Oncology Biosimilars Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Oncology Biosimilars Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Oncology Biosimilars Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Oncology Biosimilars Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Oncology Biosimilars Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Oncology Biosimilars Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Oncology Biosimilars Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Oncology Biosimilars Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Oncology Biosimilars Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Oncology Biosimilars Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Oncology Biosimilars Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Oncology Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Celltrion Corporation Information
    Table 43. Celltrion Description and Business Overview
    Table 44. Celltrion Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 45. Celltrion Oncology Biosimilars Product
    Table 46. Celltrion Recent Development
    Table 47. Biocon Corporation Information
    Table 48. Biocon Description and Business Overview
    Table 49. Biocon Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 50. Biocon Product
    Table 51. Biocon Recent Development
    Table 52. Dr. Reddy’s Laboratories Corporation Information
    Table 53. Dr. Reddy’s Laboratories Description and Business Overview
    Table 54. Dr. Reddy’s Laboratories Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 55. Dr. Reddy’s Laboratories Product
    Table 56. Dr. Reddy’s Laboratories Recent Development
    Table 57. STADA Arzneimittel AG Corporation Information
    Table 58. STADA Arzneimittel AG Description and Business Overview
    Table 59. STADA Arzneimittel AG Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 60. STADA Arzneimittel AG Product
    Table 61. STADA Arzneimittel AG Recent Development
    Table 62. Intas Pharmaceuticals Corporation Information
    Table 63. Intas Pharmaceuticals Description and Business Overview
    Table 64. Intas Pharmaceuticals Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 65. Intas Pharmaceuticals Product
    Table 66. Intas Pharmaceuticals Recent Development
    Table 67. Pfizer Corporation Information
    Table 68. Pfizer Description and Business Overview
    Table 69. Pfizer Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 70. Pfizer Product
    Table 71. Pfizer Recent Development
    Table 72. Sandoz International Corporation Information
    Table 73. Sandoz International Description and Business Overview
    Table 74. Sandoz International Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 75. Sandoz International Product
    Table 76. Sandoz International Recent Development
    Table 77. Teva Pharmaceutical Industries Ltd Corporation Information
    Table 78. Teva Pharmaceutical Industries Ltd Description and Business Overview
    Table 79. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 80. Teva Pharmaceutical Industries Ltd Product
    Table 81. Teva Pharmaceutical Industries Ltd Recent Development
    Table 82. Apotex Corporation Information
    Table 83. Apotex Description and Business Overview
    Table 84. Apotex Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 85. Apotex Product
    Table 86. Apotex Recent Development
    Table 87. BIOCAD Corporation Information
    Table 88. BIOCAD Description and Business Overview
    Table 89. BIOCAD Oncology Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 90. BIOCAD Product
    Table 91. BIOCAD Recent Development
    Table 92. Key Raw Materials Lists
    Table 93. Raw Materials Key Suppliers Lists
    Table 94. Oncology Biosimilars Customers List
    Table 95. Oncology Biosimilars Distributors List
    Table 96. Research Programs/Design for This Report
    Table 97. Key Data Information from Secondary Sources
    Table 98. Key Data Information from Primary Sources
List of Figures
    Figure 1. Oncology Biosimilars Product Picture
    Figure 2. Global Oncology Biosimilars Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Oncology Biosimilars Market Size 2017-2028 (US$ Million)
    Figure 4. Global Oncology Biosimilars Sales 2017-2028 (K Units)
    Figure 5. United States Oncology Biosimilars Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Oncology Biosimilars Market Size 2017-2028 (US$ Million)
    Figure 7. United States Oncology Biosimilars Sales 2017-2028 (K Units)
    Figure 8. United States Oncology Biosimilars Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Oncology Biosimilars Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Oncology Biosimilars Report Years Considered
    Figure 11. Product Picture of Monoclonal Antibody
    Figure 12. Product Picture of Hematopoietic Agents
    Figure 13. Product Picture of G-CSF
    Figure 14. Product Picture of Others
    Figure 15. Global Oncology Biosimilars Market Share by Type in 2022 & 2028
    Figure 16. Global Oncology Biosimilars Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 17. Global Oncology Biosimilars Sales Market Share in Value by Type (2017-2028)
    Figure 18. Global Oncology Biosimilars Sales by Type (2017-2028) & (K Units)
    Figure 19. Global Oncology Biosimilars Sales Market Share in Volume by Type (2017-2028)
    Figure 20. Global Oncology Biosimilars Price by Type (2017-2028) & (US$/Unit)
    Figure 21. United States Oncology Biosimilars Market Share by Type in 2022 & 2028
    Figure 22. United States Oncology Biosimilars Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 23. United States Oncology Biosimilars Sales Market Share in Value by Type (2017-2028)
    Figure 24. United States Oncology Biosimilars Sales by Type (2017-2028) & (K Units)
    Figure 25. United States Oncology Biosimilars Sales Market Share in Volume by Type (2017-2028)
    Figure 26. United States Oncology Biosimilars Price by Type (2017-2028) & (US$/Unit)
    Figure 27. Product Picture of Retail Pharmacies
    Figure 28. Product Picture of Hospital Pharmacy
    Figure 29. Product Picture of Online Pharmacy
    Figure 30. Global Oncology Biosimilars Market Share by Application in 2022 & 2028
    Figure 31. Global Oncology Biosimilars Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 32. Global Oncology Biosimilars Sales Market Share in Value by Application (2017-2028)
    Figure 33. Global Oncology Biosimilars Sales by Application (2017-2028) & (K Units)
    Figure 34. Global Oncology Biosimilars Sales Market Share in Volume by Application (2017-2028)
    Figure 35. Global Oncology Biosimilars Price by Application (2017-2028) & (US$/Unit)
    Figure 36. United States Oncology Biosimilars Market Share by Application in 2022 & 2028
    Figure 37. United States Oncology Biosimilars Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 38. United States Oncology Biosimilars Sales Market Share in Value by Application (2017-2028)
    Figure 39. United States Oncology Biosimilars Sales by Application (2017-2028) & (K Units)
    Figure 40. United States Oncology Biosimilars Sales Market Share in Volume by Application (2017-2028)
    Figure 41. United States Oncology Biosimilars Price by Application (2017-2028) & (US$/Unit)
    Figure 42. North America Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 43. North America Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 44. U.S. Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Canada Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Europe Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 47. Europe Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 48. Germany Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. France Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 50. U.K. Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Italy Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Russia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Asia-Pacific Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 54. Asia-Pacific Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 55. China Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Japan Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 57. South Korea Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 58. India Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Australia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. Taiwan Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. Indonesia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Thailand Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Malaysia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Philippines Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Latin America Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 66. Latin America Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 67. Mexico Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Brazil Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 69. Argentina Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 70. Middle East & Africa Oncology Biosimilars Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 71. Middle East & Africa Oncology Biosimilars Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 72. Turkey Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Saudi Arabia Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 74. U.A.E Oncology Biosimilars Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 75. Oncology Biosimilars Value Chain
    Figure 76. Oncology Biosimilars Production Process
    Figure 77. Channels of Distribution
    Figure 78. Distributors Profiles
    Figure 79. Bottom-up and Top-down Approaches for This Report
    Figure 80. Data Triangulation
    Figure 81. Key Executives Interviewed